Research programme - anti-cancer antibodies - Reverb Therapeutics
Latest Information Update: 06 Dec 2023
At a glance
- Originator Reverb Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Interleukin 15 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer